New immune cell therapy tested for tough blood cancers in japan
NCT ID NCT06253663
Summary
This study is testing an experimental treatment called KTE-X19, a type of CAR T-cell therapy, in Japanese adults whose mantle cell lymphoma or acute lymphoblastic leukemia has returned or not responded to prior treatments. The main goals are to see how well the treatment works and how safe it is for these specific patients. Researchers will measure if the cancers shrink or go away completely after receiving the therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiba University Hospital
Chiba, 260-8677, Japan
-
Hokkaido University Hospital
Hokkaido, 060-8648,, Japan
-
Juntendo University Hospital
Tokyo, 113-8431, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
Okayama University Hospital
Okayama, 700-8558, Japan
-
Tohoku University Hospital
Miyagi, 980-8574, Japan
-
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
Tokyo, 113-8677, Japan
Conditions
Explore the condition pages connected to this study.